Original articleBrimonidine 0.2% versus dorzolamide 2% each given three times daily to reduce intraocular pressure☆
Section snippets
Methods
In this study we included patients who met the following inclusion criteria: 18 years of age or older, a clinical diagnosis of primary open-angle glaucoma or ocular hypertension in at least one eye (study eye), an intraocular pressure controllable on one drug therapy in the study eye(s) in such a way that ensured clinical stability of vision and the optic nerve throughout the trial, baseline intraocular pressure of 22 to 34 mm Hg in the study eye(s) (in eyes not included in the study, the
Results
We enrolled 42 patients in this crossover comparison. Two patients withdrew consent during a study period (see below under adverse events). Of patients finishing the trial, 24 had ocular hypertension and 16 primary open-angle glaucoma. Twenty-three were female and 17 male; 21 were white and 19 black. The average age was 57.7 ± 13.3 years.
Baseline intraocular pressure for all 40 patients was 24.1 ± 2.0 mm Hg. After 6 weeks of therapy the trough intraocular pressure for the dorzolamide group was
Discussion
Dorzolamide 2% is a topical carbonic anhydrase inhibitor that was released in 1995 by Merck to provide a safer alternative to the oral carbonic anhydrase inhibitor, acetazolamide, in the treatment of primary open-angle glaucoma or ocular hypertension. Dorzolamide has been a popular adjunctive agent and frequently is used as monotherapy. Dosing for dorzolamide is labeled three times daily, but it may be tried twice daily.6 Dorzolamide reduces the intraocular pressure by 10% to 26% as a
References (17)
- et al.
MK-507 versus sezolamidecomparative efficacy of two topically active carbonic anhydrase inhibitors
Ophthalmology
(1991) - et al.
A randomized trial comparing the dorzolamide–timolol combination given twice daily to monotherapy with timolol and dorzolamide. Dorzolamide–Timolol Study Group
Ophthalmology
(1998) - Book SA. Essentials of statistics. New York: McGraw Hill Book Company,...
A double-masked crossover study comparing the effects of carteolol 1% and 2% on intraocular pressure
Acta Ophhtalmologica
(1987)- et al.
Efficacy and safety of timolol solution once daily vs. timolol gel in treating elevated IOP
J Glaucoma
(1998) - et al.
Dose response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor
Arch Ophthalmol
(1992)
Cited by (52)
Evaluation and treatment of glaucoma 24 hours a day. Where are we and where are we going?
2020, Archivos de la Sociedad Espanola de OftalmologiaCarbonic anhydrase inhibitors as fourth drug in primary glaucomas: Is it worth it?
2015, Canadian Journal of OphthalmologyCitation Excerpt :In 1 subject, the mean IOP reached a 3.7-mm Hg (33%) increase compared with baseline. Considering the percentage of the mean IOP changes, there was a significant increase (defined as an IOP change ≥20%; based on previously reported drug effect data6–14) after the drug removal in 5 patients (20%), all of whom were older than 60 years. Older patients were more influenced by drug interruption (Fig. 1).
Brimonidine Tartrate 0.15%, Dorzolamide Hydrochloride 2%, and Brinzolamide 1% Compared as Adjunctive Therapy to Prostaglandin Analogs
2009, OphthalmologyCitation Excerpt :Despite the increased drug exposure caused by use of a thrice-daily dosing schedule, each of the study medications was well tolerated, and all enrolled patients completed the study as planned. Previous studies using the study drugs as monotherapy have suggested that brimonidine reduces IOP more effectively than dorzolamide only at peak effect (2 hours after dosing),20,21 whereas dorzolamide and brinzolamide have comparable efficacy in reducing IOP throughout the day.22 The efficacy of drugs used as adjunctive therapy may or may not mirror their efficacy when used as monotherapy.
The adrenergic system and adrenergic agonists
2009, Becker-Shaffer's Diagnosis and Therapy of the Glaucomas: Eighth Edition24-Hour intraocular pressures with brimonidine purite versus dorzolamide added to latanoprost in primary open-angle glaucoma subjects
2005, OphthalmologyCitation Excerpt :This study provided an 80% power that a 1.5-mmHg difference could be excluded between groups if 27 subjects completed the study. An SD of 2.8 mmHg was assumed.1,6–8 A Bonferroni correction at individual time points to adjust the P value for multiple measures was used within families of data based on clinical importance.
Efficacy and safety of various brimonidine formulations in the treatment of glaucoma and ocular hypertension
2021, Fyodorov Journal of Ophthalmic Surgery
- ☆
This work was sponsored by an unrestricted grant from Merck, Inc, and in part by an unrestricted grant from Research to Prevent Blindness, Inc.